BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
BioVie and Mobilicom will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing June 22 at 7 p.m. ET. BioVie's CEO, Cuong Do, discusses the company's late-stage clinical programs targeting neurodegeneration and liver disease, highlighting their lead asset, bezisterim, which has shown promising results in clinical trials for Parkinson's and Alzheimer's diseases. Key milestones include a Phase 2b trial for Parkinson's in Fall 2024 and a Phase 3 trial for Alzheimer's in mid-2025.
Mobilicom's CEO, Oren Elkayam, will talk about their investment opportunities. Mobilicom's products, like SkyHopper Datalinks and the ICE Cybersecurity Suite, have led to significant market penetration, with 50 customers in 18 countries. The company achieved 43% revenue growth and a 59% gross margin in 2023, ending the year with $8.4 million in cash, indicating a solid financial position to execute their strategic plans.
- BioVie’s bezisterim has shown significant clinical improvements in Parkinson's and Alzheimer's diseases.
- BioVie plans to initiate a Phase 2b trial for Parkinson's in Fall 2024 and a Phase 3 trial for Alzheimer's in mid-2025.
- Mobilicom achieved 43% revenue growth and a 59% gross margin in 2023.
- Mobilicom ended 2023 with a strong cash balance of $8.4 million.
- None.
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
BioVie: https://www.redchip.com/assets/access/bivi_access
Mobilicom: https://www.redchip.com/assets/access/mob_access
In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's lead asset, bezisterim (formerly NE3107), has demonstrated the ability to modulate TNFα production, leading to significant clinical improvements. Patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in Parkinson's disease (PD), enhanced cognition and function, and better brain imaging scans in Alzheimer's disease (AD), as well as reduced DNA methylation levels. The Company's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnering discussions for bezisterim's geographic rights, and commencing an ascites Phase 3 trial upon identifying a suitable partner.
Oren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a strong investment opportunity with its comprehensive and proprietary technology suite. The company's products, including SkyHopper Datalinks, Ground Control Systems, Mobile Mesh Networking, the ICE Cybersecurity Suite, and CONTROLiT cloud management, form the core 'brain' of drones, providing control, guidance, and cybersecurity. Mobilicom's intellectual property, comprising trade secrets and 34 patent claims across two patent families, underscores its innovation leadership. With a global footprint, the company has secured over 50 customers in 18 countries and achieved 50 "design wins," indicating significant market penetration and long-term revenue potential. Mobilicom generated
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of ERK and NFκB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration ("FDA") Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.
About Mobilicom
Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom's large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world's largest drone manufacturers, Mobilicom's end-to-end solutions are used in mission-critical functions.
For investors, please use https://ir.mobilicom.com/
For company, please use www.mobilicom.com
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will BioVie and Mobilicom appear on Bloomberg TV?
What are BioVie's strategic priorities for bezisterim?
What clinical improvements has BioVie's bezisterim shown?
What are Mobilicom's key financial achievements in 2023?
How many customers does Mobilicom have globally?
